Facebook
X
LinkedIn
ForwardSymposium Guide
Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies, Seventh Annual
Friday-Saturday, March 6-7, 2026
Test
Quick Links
Claim CME/CE Credit
Option 1: Text the six-letter code provided at the end of each day's session to (754) 203-8885. You will receive a message confirming your attendance.
Option 2: Scan the QR code shown below with your mobile phone, and enter the six-letter code provided at the symposium to receive your credit.
Evaluation
Once you have claimed your CME/CE credit, you will receive a link to your daily evaluation form via email and SMS.
Presentations
Friday, March 6 | 6.25 Cat. 1
| 7:30 - 8:30 a.m. | Breakfast & Visit Exhibits- Product Theater |
| 8:30 - 8:45 a.m. | Welcome and Introductions Guenther Koehne, M.D., Ph.D. |
| Multiple Myeloma | |
| 8:45 - 9:05 a.m. | Maintenance Therapy Post Autologous Transplants: Does MRD status Affect the Treatment Choice? Saad Usmani, M.D. |
| 9:05 - 9:25 a.m. | Redirecting Therapies for Relapse/Refractory Multiple Myeloma by CAR T and Bites Adam Cohen, M.D. |
| 9:25 - 9:45 a.m. | Integration of CellMods into Treatment Approaches for Multiple Myeloma Paul Richardson, M.D. |
| 9:45 - 10:05 a.m. | Insights on Adapting Treatments for Multiple Myeloma with New Immunotherapies in Countries with Limited or Intermediate Resources Patricio Duarte, M.D. |
| 10:05 - 10:25 a.m. | How to Treat AL Amyloidosis in 2026 Heather Landau, M.D. |
| 10:25 - 10:45 a.m. | Panel Discussion Moderator & Faculty |
| 10:45 - 11:05 a.m. | Break and Visit Exhibits |
| B- and T-Cell Malignancies | |
| 11:05 - 11:25 a.m. | Novel Therapies in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Matthew Matasar, M.D. |
| 11:25 - 11:45 a.m. | Novel therapies in Chronic Lymphocytic Leukemia (CLL) Craig Sauter, M.D. |
| 11:45 - 12:05 p.m. | Overcoming Treatment Resistance in T-All: Translation to the Clinic Wendy Stock, M.D. |
| 12:05 - 12:20 p.m. | Panel Discussion Moderator & Faculty |
| 12:20 - 12:50 p.m. | Lunch and Exhibits |
| 12:50 - 1:20 p.m. | Product Theater |
| Acute Leukemia | |
| 1:20 - 1:40 p.m. | AML 2026: Is 7+3 Still the Standard of Care? Richard Stone, M.D. |
| 1:40 - 2:00 p.m. | Updates on Targeted Therapies in Acute Myeloid Leukemia Eytan Stein, M.D. |
| 2:00 - 2:20 p.m. | LYT-200 An Anti-Galectin 9 Antibody, for Treatment of AML/High-risk TBD |
| 2:20 - 2:35 p.m. | Panel Discussion Moderator & Faculty |
| 2:35 - 2:50 p.m. | Break and Visit Exhibits |
| Myeloproliferative Disorders | |
| 2:50 - 3:10 p.m. | Novel Therapeutic Strategies in Myelofibrosis Raajit K. Rampal, M.D., Ph.D. |
| 3:10 - 3:30 p.m. | The Role of PIM Kinase Inhibition in Myelofibrosis Firas El Chaer, M.D. |
| 3:30 - 3:50 p.m. | Myelofibrosis: Who to Transplant and Who Not to Transplant? Nicolaus Kroeger, M.D. |
| 3:50 - 4:05 p.m. | Panel Discussion Moderator & Faculty |
| 4:05 - 4:15 p.m. | Closing Remarks/Adjourn Guenther Koehne, M.D., Ph.D. |
Saturday, March 7 | 4.25 Cat. 1
| 8:00 – 8:30 a.m. | Registration and Breakfast, Visit Exhibits and Product Theater |
| Updates on CAR Therapies | |
| 8:30 – 8:50 a.m. | Next Steps in CAR T-Cell Therapies Michel Sadelain, M.D., Ph.D. |
| 8:50 – 9:10 a.m. | Optimizing CAR T-Cell Homing via GPS Robert Sackstein, M.D., Ph.D. |
| 9:10 – 9:30 a.m. | Do CARs Always Have to be T-Cells? Paul Lin, M.D. |
| 9:30 – 9:50 a.m. | The Role of Intestinal Microbiome in Cancer Immunotherapy TBD |
| 9:50 – 10:05 a.m. | Panel Discussion Moderator & Faculty |
| 10:05 – 10:50 a.m. | Break, Visit Exhibits and Product Theater |
| Allogeneic Stem Cell Transplants | |
| 10:50 – 11:10 a.m. | Myelodysplastic Syndrome (MDS): Who to Transplant and Who Not to Transplant? Wael Saber, M.D. |
| 11:10 – 11:30 a.m. | Novel Insights in the Development of Acute GVHD Alan Hanash, M.D. |
| 11:30 – 11:50 a.m. | Novel Approaches to GVHD Prevention and Therapy Corey Cutler, M.D. |
| 11:50 – 12:05 p.m. | Panel Discussion Moderator & Faculty |
| 12:05– 12:20 a.m. | Break and Visit Exhibits |
| 12:20 – 12:40 p.m. | Donor and Graft Source Optimization for Allo Transplant Robert Soiffer, M.D. |
| 12:40 – 1:00 p.m. | Redifining Preventation - What’s Next for GVHD Prophalaxis? Leo Luznik, M.D. |
| 13:00 – 1:20 p.m. | Is it time for post-transplant maintenance therapies in AML? Guenther Koehne, M.D., Ph.D. |
| 1:20 – 1:35 p.m. | Panel Discussion Moderator & Faculty |
| 1:35 – 1:45 p.m. | Closing Remarks and Adjourn |
NOTE: Schedule subject to change.
Disclosures And Resolution of Conflict of Interest Disclosure Policy and Disclaimer
